Perceptive Advisors’s Nuvectis Pharma NVCT Stock Holding History

Perceptive Advisors’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.4M	Buy	+1,000,000	New	+$11.2M	0.28%	62

Other funds holding NVCT

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Perceptive Advisors's NVCT Position: Q2 2026 in Review

Perceptive Advisors opened a new position in Nuvectis Pharma (NVCT) in Q2 2026: 1,000,000 shares worth $18.4M. The stake represents 0.28% of the portfolio and ranks #62 among its holdings.

83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

Perceptive Advisors held 1,000,000 shares of Nuvectis Pharma worth $18.4M as of Q2 2026.
Nuvectis Pharma was a new Perceptive Advisors position in Q2 2026.
Nuvectis Pharma made up 0.28% of Perceptive Advisors's portfolio in Q2 2026, its #62 holding.
83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.